Sabrina He focuses her practice on mergers and acquisitions, private equity, venture capital and general corporate matters. Sabrina advises multinational clients on various aspects of transactions, foreign direct investment and operations in China. She also represents Chinese companies on their outbound M&A transactions and related M&A finance in regions such as North America, South America and Europe. She also frequently advises emerging biotech and pharmaceutical companies, venture capital and corporate investors on financing and licensing transactions. She is fluent in English and Mandarin Chinese.
Advised a Chinese state-owned financial institution on its proposed acquisition of global operations of a U.S. auto parts manufacturer for around US$400 million from a U.S. private equity fund.
Advised China Minmetals Corp./MMG on their acquisition of the Las Bambas copper mine project in Peru from Glencore Xstrata plc for US$5.85 billion.
Advised a Chinese conglomerate on its proposed acquisition of a U.S. baby product designer and retailer for around US$150 million from PE sellers and founders in an auction sale.
Advised a Chinese PCB manufacturer on its proposed acquisition of 100% of share capital of a Singapore-based PCB manufacturer for around US$150 million in an auction sale.
Advised founders and a U.S.-based private equity fund on their sale of global operations of a U.S.-headquartered company engaging in third-party call center services to a U.S.-based private equity fund for around US$1 billion.
Advised a U.S. engineering company on its acquisition of a global EPC business relating to mining and oil and gas markets from a Norwegian industrial company for US$675 million.
Foreign Direct Investment
Advised a UK insurance company on its China joint venture with four Chinese investors (one insurer and three financial investors) to engage in online financial services.
Advised a U.S. aluminum product manufacturer on its joint venture in China with a total investment of US$500 million to produce aluminum aircraft and automobile body sheets, and other acquisition and joint venture efforts in China.
Advised a U.S. contract sterilization service provider on its proposed acquisition of a Shanghai-based irradiation sterilization facility.
Life Sciences & Healthcare
Advised a U.S. healthcare fund on its Series C and pre-U.S. IPO investment in a Shanghai-based biopharmaceuticals developer.
Advised a Chinese listed pharmaceutical company on its investment into a U.S. In Vitro diagnosis company.
Advised a Chinese pharmaceutical R&D company on its Series B financing in China and abroad.
Advised a U.S. pharmaceutical startup with presence in Shanghai on its exclusive licensing agreement with a German pharmaceutical company.
Advised an Australian hospital group on its proposed pre-IPO financing of a Chinese privately owned hospital to be listed in Hong Kong.
Advised Phoenix Healthcare Group Co. Ltd, China's largest private hospital group, in its IPO on the Hong Kong Stock Exchange.